India, Aug. 19 -- Dr. Reddy's Laboratories Ltd. has launched Versavo(R) (bevacizumab), a biosimilar of Roche's Avastin(R) in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer).

Dr. Reddy's Versavo(R) is available in strengths of 100mg and 400mg single use vials. Commenting on the launch, MV Ramana, CEO - India and Emerging Markets, Dr. Reddy's Laboratories, said, "We regard the good health of our patients as our responsibility and are committed to ensure that they always have access to the...